摘要
目的:研究改良的泪囊鼻腔吻合术在治疗慢性泪囊炎中的应用价值。方法:将2016年2月至2017年2月金堂县第二人民医院收治的80例慢性泪囊炎患者作为研究对象。对这80例患者均实施泪囊鼻腔吻合术,然后分析其手术的时间、术中的出血量、住院的时间、住院的费用、临床疗效及发生术后出血、鼻黏膜损伤、鼻腔泪囊吻合孔黏膜增生等并发症的情况。在对这些患者进行治疗后的第12个月、第24个月分别观察其病情的复发率。对比分析这些患者在接受治疗前后其溢泪程度评分、泪膜破裂时间(BUT)及进行泪液分泌实验Ⅰ(SchirmerⅠ)的情况。结果:本组患者治疗的总有效率为97.5%,其并发症的发生率为7.5%。在术后12个月,本组患者病情的复发率为2.5%。在术后24个月,本组患者病情的复发率为5%。与进行治疗前相比,本组患者在进行治疗后其溢泪程度评分、BUT及SchirmerⅠ实验指标均较低,差异有统计学意义,P<0.05。结论:为慢性泪囊炎患者采用改良的泪囊鼻腔吻合术进行治疗可取得显著的临床疗效,而且安全性较高。
objective： to study the value of improved dacryocystorhinostomy in the treatment of chronic dacryocystitis. Methods： 80 patients with chronic dacryocystitis admitted to jintang county second people＇s hospital from February 2016 to February 2017 were studied. For the implementation of the lacrimal sac nasal anastomosis in all 80 cases, and then analyze its operation time, intraoperative blood loss, hospitalization time, hospitalization expenses of, clinical curative effect and the occurrence of postoperative bleeding, nasal mucosa damage, nasal lacrimal sac anastomosis complications such as hole mucous membrane hyperplasia. The recurrence rates were observed at 12 months and 24 months after treatment. Comparative analysis on these patients before and after treatment the overflow tears degree score, appears rupture time（BUT） and tear secretion experiments Ⅰ（Schirmer Ⅰ）. Results： the total effective rate was 97.5%, and the incidence of complications was 7.5%. At 12 months after surgery, the recurrence rate was 2.5%. At 24 months after surgery, the recurrence rate of patients in this group was 5%. Compared with before treatment, the patients in the treatment after the score, BUT the degree of the overflow tears and Schirmer Ⅰ experimental indexes is low, the difference was statistically significant, P〈0.05. Conclusion： the improved dacryocystorhinostomy is effective and safe for chronic dacryocystitis.
作者
谢泽辉
Xie Zehui(Jintang county second people＇ s hospital, jintang sichuan 610400)
关键词
泪囊鼻腔吻合术
慢性泪囊炎
应用价值
dacryocyst nasal anastomosis
Chronic dacryocystitis
Application value
